Updates are available Correction dated 2016-05-20

Article History

First Online: 25 April 2016

Compliance with Ethical Standards

: Medical writing and editorial support was provided by Pia Sondergeld (University of Giessen, Germany) and was funded by Janssen.

: Philippe Moreau received fees for advisory board participation from Janssen, Celgene, Bristol–Myers Squibb, Novartis, Takeda, and Amgen. Niels W. C. J. van de Donk received a research Grant from Celgene, Janssen Pharmaceuticals, and Amgen. Jesus San Miguel received fees for advisory board participation from Millennium, Celgene, Novartis, Onyx, Janssen, Bristol–Myers Squibb, and Merck Sharp and Dohme. Henk Lokhorst received fees for attending advisory boards on daratumumab (Janssen). Michele Cavo received honoraria from Janssen, Cilag, Takeda, and Bristol–Myers Squibb, and payment for lectures from Janssen, Cilag, and Takeda. Gordon Cook received Grants from Janssen, Celgene, Takeda, and Chugai-Pharmaceutical Co.; consulting fees or honorarium from Janssen, Celgene, Takeda, Sanofi, Bristol–Myers Squibb, Glycomimetics, and Amgen; support for travel from Janssen, Celgene, Takeda, Sanofi; fees for participation in review activities from Celgene, and Glycomimetics; and payment for lectures from Janssen, Celgene, Takeda, Sanofi, Bristol–Myers Squibb, and Amgen. Michel Delforge received a Grant from Celgene (phase IV clinical trial), and honoraria from Amgen, Celgene, Janssen, Novartis, and Takeda. Hermann Einsele received consulting fees or honorarium, payment for lectures, and support for travel from Janssen, Celgene, Amgen, and Novartis. Sonja Zweegman received honoraria for advisory board participation from Celgene, Takeda, Janssen, and Novartis (honorarium for departmental use, not personal use), and lectures for Celgene and Janssen (payment for departmental use only). Heinz Ludwig received fees for participation in data monitoring committees of early daratumumab studies. Christoph Driessen received consulting honorarium related to daratumumab from Janssen–Cilag (not related to the current manuscript). Antonio Palumbo received consulting fees and honoraria from Janssen–Cilag (not related to the current manuscript). Thierry Facon received fees for advisory board participation, as well as support for travel and payment for lectures from Janssen. He undertakes advisory board activities with Janssen and is on the speaker’s bureau for Janssen. Torben Plesner received a research Grant from Janssen, honoraria for advisory board participation from Genmab and Janssen, and payment for lectures from Janssen. Meletios Dimopoulos has received consulting fees or honoraria from Janssen, Celgene, Novartis, and Amgen. Pia Sondergeld received payment from Janssen for the writing of this manuscript. Pieter Sonneveld received Grants from Amgen, Celgene, Janssen, and Karyopharm; consulting fees or honoraria from Amgen, Celgene, Janssen, and Karyopharm; fees for participation in review activities from Celgene and Janssen; provision of writing assistance from Janssen; and payment for lectures from Amgen, Celgene, and Janssen. He has been involved in drug research, i.e. clinical trials, both investigator-initiated and company-initiated, and has served on advisory boards and given lectures in the context of new drug development for multiple myeloma. Maria-Victoria Mateos has received honoraria for lectures and participation in advisory boards from Janssen, Celgene, Takeda, Amgen, and Bristol–Myers Squibb. Hareth Nahi and Dina Ben-Yehuda have no conflicts of interest to declare.